ReviewCancer management and research2020

Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date.

Vincent Chau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.